NL-OMON56986尚未招募不适用
Clinical Performance Study Protocol for Use of VENTANA PD-L1(SP263) CDx Assay in GSK Study 213823 (GALAXIES LUNG-301) - GSK GALAXIES LUNG-301 PD-L1
Ventana Medical Systems, Inc. (Roche Tissue Diagnostics)0 个研究点目标入组 10 人开始时间: 待定最近更新:
适应症
试验速览
- 阶段
- 不适用
- 状态
- 尚未招募
- 发起方
- 入组人数
- 10
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 18 至 99（—）
入选标准
- •To be included in this Dx protocol, a specimen must meet all of the following
- •1. It must be a formalin-fixed, paraffin embedded (FFPE) tumor
- •specimen submitted for central PD-L1 testing for the GALAXIES
- •LUNG-301 Study and processed in accordance with standard
- •2. It must contain sufficient tumor tissue for interpretation at the
- •discretion of the reviewing pathologist; and
- •3. If an FFPE tissue block is unavailable, unstained FFPE slides can be
排除标准
- •A specimen will be excluded from the Dx protocol if any of the following
- •criteria are true:
- •1. It is known to be fixed in 95% alcohol, alcohol-formalin-acetic acid
- •(AFA), or PREFER;
- •2. It is a fine needle aspirate (FNA), cytology, bone marrow or bone
- •3. It consists of tissue containing bone that has been decalcified*; or
- •4. Cut slides were prepared more than 12 months prior to staining.
- •*Prior to testing any specimen, evidence of decalcification must be
- •obtained.This information may
- •be obtained from the pathology report. If the pathology report is not available
- •or does not specify
- •whether the sample was decalcified or not, the sample must be held and the
- •submitting site
- •queried. If the sample has been decalcified, testing cannot proceed.
研究者
相似试验
尚未招募
3 期
Clinical Performance Study Protocol for Use of VENTANA PD-L1 (SP263) CDx Assay in AstraZeneca Study D798AC00001(eVOLVE-Lung02): A Phase III, Two-Arm, Parallel, Randomized, Multi-Center, Open-Label, Global Study to Determine the Efficacy of Volrustomig (MEDI5752) Plus Chemotherapy Versus Pembrolizumab Plus Chemotherapy for First-Line Treatment of Patients with Metastatic Non-Small Cell Lung Cancer (mNSCLC) (eVOLVE-Lung02)Metastatic Non-Small Cell Lung Cancer with PD-L1<50%10027476Non-Small Cell Lung CancerNL-OMON56319Astra Zeneca32
尚未招募
1 期
Panchakarma, Ayurveda, Emesis, Powder massage, hypothyroidismCTRI/2020/01/022809Dr Mallika Singh
进行中（未招募）
1 期
Clinical study to investigate whether in patients with peripheral artery disease, after implantation of a stent and showing high platelet reactivity during treatment with clopidogrel, treatment with ticagrelor is able to prevent effectively vascular occlusioEUCTR2014-001989-97-ATOA Doz. Dr. Thomas Müller c/o B&S Zentrallabor Konventhospital Barmherzige Brüder Linz500
尚未招募
2 期
Clinical study to see the effect of Vrana Lepa in non-healing ulcersCTRI/2021/01/030398Sri Dharmasthala Manjunatheshwara College of Ayurveda and Hospital
招募中
2 期
A clinical study of Vranari Guggulu and Vrana lepa in the management of Diabetic Foot UlcerCTRI/2015/02/005586DrNRS GovtAyurvedic College100